Ruth March, PhD, is Senior Vice-President of AstraZeneca’s Precision Medicine function.
As a member of the senior leadership team in AstraZeneca’s R&D Oncology group, I am accountable for delivering diagnostics across AstraZeneca’s R&D pipeline to match targeted medicines to those patients most likely to benefit.
I have led the development of AstraZeneca’s industry-leading capability in precision medicine, with 16 diagnostics launched linked to 4 AstraZeneca medicines since 2014. Precision medicine is now applied in >90% of AstraZeneca’s clinical pipeline across all main therapy areas - oncology, CVRM, and respiratory disease.
I have also led an innovative approach to diagnostics, developing technologies that best fit the patient’s care pathway. In addition, I have led over $185M investment with diagnostic partners, including molecular diagnostics, tissue diagnostics, next generation sequencing and point of care diagnostics.
With my team, I have pioneered many industry firsts:
- 1st drug label extension based on circulating tumour DNA (ctDNA), making targeted therapy available to up to 40% of patients with lung cancer who cannot provide a solid tumour tissue sample
- 1st laboratory based companion diagnostic (which detects thousands of mutations in BRCA genes classified through a diagnostic algorithm)
- 1st companion diagnostic based on both ctDNA and tissue in the resistance setting
- 1st point of care diagnostic approved in inflammation
- 1st prototype point of care diagnostic for eosinophilic asthma
I am a genomics specialist with over 50 patents and publications and I drew on my extensive academic research to lead the first genome-wide single-nucleotide polymorphism analysis of a safety biomarker to be submitted to the FDA.
WORLD LEADING GENOMICS STRATEGY
FIRST CIRCULATING TUMOUR DNA APPROVAL
Drug target genes associated with clinical phenotypes in the genetically isolated population of Finland more likely to succeed in pharmaceutical development皇冠官网手机版
Drug target genes associated with clinical phenotypes in the genetically isolated population of Finland more likely to succeed in pharmaceutical development. R March, M Cunha, C Elks, A Platt, M Alanen-Kinnunen, S Lemmelä, V Salomaa, P Jousilahti, M Daly, D Goldstein and A Palotie. ASHG 2017 Meeting abstract.
Lessons learned from the fate of AstraZeneca's drug pipeline 皇冠官网手机版
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. D Cook, D Brown, R Alexander, R E March, P Morgan, G Satterthwaite & M N Pangalos. Nature Reviews Drug Discovery 13, 419-431 (June 2014) | doi:10.1038/nrd4309
Genome-wide pharmacogenetic investigation of a hepatic adverse event皇冠官网手机版
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. A Kindmark, A Jawaid, C G Harbron, B J Barratt, O F Bengtsson, T B Andersson, S Carlsson, K E Cederbrant, N J Gibson, M Armstrong, M E Lagerström-Fermér, A Dellsén, E M Brown, M Thornton, C Dukes, S C Jenkins, M A Firth, G O Harrod, T H Pinel, S M E Billing-Clason, L R Cardon and R E March. The Pharmacogenomics Journal (2008) 8, 186–195; doi:10.1038/sj.tpj.6500458
I believe personalised healthcare is the future of medicine; it allows us to use the latest diagnostic science to target medicines to patients most likely to benefit.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.